A peptide prodrug approach for improving bisphosphonate oral absorption

Journal of Medicinal Chemistry

Volumn 43, Issue 20, 2000, Pages 3641-3652

  Ezra, A ^a   Hoffman, A ^a   Breuer, E ^b   Alferiev, I S ^b   Monkkonen J ^c   El Hanany Rozen, N ^b   Weiss, G ^b   Stepensky, D ^a   Gati, I ^a   Cohen, H ^a   Tormalehto S ^c   Amidon, G L ^d   Golomb, G ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DRUG CARRIER; PAMIDRONIC ACID; PRODRUG;

ANIMAL EXPERIMENT; ARTICLE; CALCIFICATION; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; INTESTINE; NONHUMAN; RAT; STOMACH ABSORPTION;

ADMINISTRATION, ORAL; ALENDRONATE; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CARRIER PROTEINS; DIPEPTIDES; DIPHOSPHONATES; DURAPATITE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; PRECIPITATION; PRODRUGS; RATS; SYMPORTERS; TISSUE DISTRIBUTION;

EID: 0034609777     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980645y     Document Type: Article

References (39)

1. Bisphosphonates spearhead new approach to treating bone metastases
2. Bisphosphonates: Preclinical aspects and use in osteoporosis
3. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
4. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
5. Alendronate treatment for osteoporosis: A review of the clinical evidence
6. Absorption of oral diphosphonate in normal subjects
7. Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration
8. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals
9. Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey
10. Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals
11. On the absorption of alendronate in rats
12. Sodium EDTA enhances intestinal absorption of two bisphosphonates
13. Use of bisphosphonates in cancer patients
14. Pharmaceutical and pharmacological relevance 1. Drug transport and targeting - Intestinal transport
15. Intestinal absorption mechanism of amphoteric β-lactam antibiotics II: Michaelis-Menten kinetics of cyclacillin absorption and its pharmacokinetic analysis in rats
16. Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and β-lactam antibiotics
17. Molecular mechanisms for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE inhibitors: Enalapril, enalaprilat, and lisinopril
18. Passive and carrier-mediated intestinal absorption components of two angiotensin-converting enzyme (ACE) inhibitor prodrugs in rats: Enalapril and fosinopril
19. Use of the peptide carrier system to improve the intestinal absorption of L-α-methyldopa: Carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa
20. Method of preparation of higher 1-hydroxyalkylidene-1,1-diphosphonic acids or their mixtures or salts. Russian Patent SU 1,719,405
21. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo
22. Bisphosphonate prodrugs: Synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate
23. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter
24. Structural specifity of mucosal cell transport and metabolism of peptide drugs: Implication for oral peptide drug delivery
25. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats
26. Mode of administration-dependent pharmacokinetics of bisphosphonates
27. The oligopeptide transporter (Pept-1) in human intestine: Biology and function
28. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system
29. Anticalcification and antiresorption effects of bisacylphosphonates
30. The evaluation of bisphosphonates as potential drugs for the treatment of calcium-related disorders
31. Chemical, biochemical, and medicinal properties of the diphosphonates
32. Bisphosphonates and tetracycline: Experimental models for their evaluation in calcium-related disorders
33. Membrane permeability parameters for some amino acids and β-lactam antibiotics: Application of boundary layer approach
34. Comparison between permeability coefficients in rat and human jejunum
35. Rat jejunal permeability and metabolism of μ-selective tetrapeptides in gastrointestinal fluids from humans and rats
36. Utilization of peptide carrier system to improve intestinal absorption: Targeting prolidase as a prodrug-converting enzyme
37. Development of a new in vitro model for studying implantable polyurethane calcification
38. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates